 

Shareholders as a
percentage of our
paid-up Equity
Share capital

 

 

 

 

 

Name Number of Equity Shares | Percentage of the pre-Offer
Equity Share Capital on a
fully diluted basis (%)

Promoters

Lone Furrow Investments Private Limited 17,233,240 15.42
Agilemed Investments Private Limited 15,649,495 14.00
Gangadi Madhukar Reddy 15,350,400 13.74
Total 48,233,135 43.16

 

 

 

 

(b) The aggregate pre-Offer shareholding of the Selling Shareholders as a percentage of the pre-Offer paid-up Equity
Share capital of our Company is set out below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name Number of Equity Shares | Percentage of the pre-Offer
held Equity Share Capital on a
fully diluted basis (%)
PI Opportunities Fund — I 24,661,385 22.07
S. S. Pharma LLC 1,850,535 1.66
Shore Pharma LLC 553,090 0.49
Natco Pharma Limited 451,205 0.40
Time Cap Pharma Labs Private Limited 450,590 0.40
‘A. Raghava Reddy 268,550 0.24
K Prakurthi 106,190 0.10
Sangeeta Raju 80,770 0.07
Navdeep Patyal 38,745, 0.03
R Venkat Reddy 29,930 0.03
TK Kurien 25,420 0.02
Nithya Venkataramani 23,165, 0.02
Atul Gupta 23,165, 0.02
Manoj Jaiswal 165 0.02
Rahul Garg 23,165, 0.02
Kollengode Ramanathan Lakshminarayana 9,225 0.01
Bijou Kurien 9,225 0.01
Total 28,627,520 25.61

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Summary of | The details of our equity share capital, net worth, revenue, profit after tax, earnings per Equity share, net asset value
Selected Financial | per equity share and total borrowings as at September 30, 2021, September 30, 2020, March 31, 2021, 2020 and 2019
Information derived from the Restated Consolidated Financial Information are as follows:
(@ in million, except per share data)
Particulars As at and for the six months As at March 31,
ended
September 30, | September 30, 2021 2020 2019
2021 2020
(A) Equity share capital 64.39 1.94 4.48 1.94 1.94
(B)_Net worth* 8,009.77 5,903.41] 7,305.53] _5,278.02|_ 2,913.37
(C) Revenue from operations 18,799.21 5 | 30,692.69 | 28,706.03 | 22,727.37
(D) Profit for the year 663.67 631.11 17.94 119.22
(E) Earnings per equity share 6.16 Ea) 0.21 1.33
(F)_ Net asset value per share (Basic) 73.71 68.48 50.90 32.55
(G) Borrowings 567.48 863.82] 1,352.35] 1,050.51] 1,044.02
* Total equity attributable to owner of the Company is equal to Net worth
Auditor’s Our Statutory Auditors have not included any qualifications in the audit report that have not been given effect to in the
qualifications Restated Consolidated Financial Information.

which have not
been given effect to
in the Restated
Consolidated
Financial
Information

 

 

Summary table of

 

A summary of outstanding litigation proceedings as disclosed in “Outstanding Litigation and Material Developments”

 

outstanding on page 304, in terms of the SEBI ICDR Regulations and the materiality policy approved by our Board pursuant to a
litigation resolution dated August 3, 2021, as of the date of this Prospectus is provided below:
(2 in million)
Name of | Criminal Tax Statutory or | Disciplinary Material | Aggregate
Regulatory _| actions by the | Civil amount

 

 

 

 

 

 

 

 

 

 
